title: Proportion of CD4+CD25+ regulatory T cell is increased in the patients with ovarian carcinoma.
abstract: OBJECTIVE
  To study the frequency of the CD4+CD25+ regulatory T cells (Tregs) in the patients with ovarian carcinoma and its possible mechanism.
  
  
  METHODS
  The percentages of CD4+CD25+ Tregs in the peripheral blood lymphocytes (PBLs), tumor infiltrating lymphocytes (TILs) and tumor associated lymphocytes (TALs) from 13 patients with ovarian carcinoma and in the PBLs from 14 healthy women were determined by flow cytometry. The expression of CD69 on CD4+PBLs from the patients was detected. PBLs from healthy women were cultured in complete RPMI 1640 containing the supernatant from SKOV3 cell line with or without PHA (phytohemagglutinin) stimulation for 72 hours, then the percentage of CD4+CD25+ T cells was detected.
  
  
  RESULTS
  CD4+CD25+ Tregs in the PBLs from patients with ovarian carcinoma were significantly increased compared with those from the control. The percentage of CD4+CD25+ Tregs in TILs was higher than that in PBLs and TALs from the patients, but not significantly. The expression of CD69 on CD4+PBLs from the patients was negative. The percentages of CD4+CD25+ T cells in PBLs cultured with SKOV3 supernatant elevated significantly compared with those without supernatant whether PHA was added or not (P=0.001 and 0.001, respectively).
  
  
  CONCLUSIONS
  There is an increasing of the proportion of CD4+CD25+ Tregs in PBLs, TILs and TALs of the patients with ovarian carcinoma, which probably results from up-regulation of soluble factor secreted by ovarian carcinoma cells.
authors.affiliation: Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Li
authors.forename: Da-Feng
authors.initials: DF
authors.lastname: Ye
authors.forename: Xing
authors.initials: X
authors.lastname: Xie
authors.forename: Huai-Zeng
authors.initials: HZ
authors.lastname: Chen
authors.forename: Wei-Guo
authors.initials: WG
authors.lastname: Lu
mesh_terms: D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D002277:Carcinoma / Q000276:immunology*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D014407:Tumor Cells, Cultured
chemical_list: D015375:Receptors, Interleukin-2